BioSpace News Archive

Freelance workers are a significant component of the biopharma industry. Join us as we take a look at a few biopharma freelancing opportunities and learn where to find them.

Elicio Therapeutics entered into a merger agreement as a wholly-owned subsidiary of Angion Biomedica Co. on Tuesday, becoming a Nasdaq-listed company.

TC BioPharm and MD Anderson signed a three-year collaboration to better understand the role of gamma delta T cells in cancer treatment.

Edesa Biotech’s EBO1, a monotherapy for moderate-to-severe chronic Allergic Contact Dermatitis (ACD), showed mixed results compared to placebo in Phase II, the company announced Tuesday.

Massachusetts-based biotech Leap Therapeutics announced Tuesday that it had entered into a merger deal with the privately-held Flame Biosciences, Inc.

Shockwave Medical bolsters medical device portfolio with acquisition of Neovasc.

Kinarus Therapeutics AG “Kinarus”, a Swiss clinical-stage biopharmaceutical company announced preclinical data supporting the potential effectiveness of its lead clinical candidate, KIN001, as an oral treatment for idiopathic pulmonary fibrosis.

Diamante S.r.l., a female-led Italian biotechnology company focused on the use of plants for producing high value-added molecules, closes Euro 595K as a second Seed Round led by Arieli Capital.

Shanghai Henlius Biotech, Inc. announced that its first self-developed innovative anti-PD-1 monoclonal antibody HANSIZHUANG, in combination with carboplatin and etoposide for the first-line treatment of extensive stage small cell lung cancer, has been approved by the National Medical Products Administration, making it the world’s first anti-PD-1 mAb for the first-line treatment of small cell lung cancer.

Dexcom G6 was the first Continuous Glucose Monitoring (CGM) System to be officially listed by the NIHB Drug Benefit program.